8 results on '"Moustafa, Mahmoud F."'
Search Results
2. Prospective Drug Candidates as Human Multidrug Transporter ABCG2 Inhibitors: an In Silico Drug Discovery Study
- Author
-
Ibrahim, Mahmoud A. A., Badr, Esraa A. A., Abdelrahman, Alaa H. M., Almansour, Nahlah Makki, Shawky, Ahmed M., Mekhemer, Gamal A. H., Alrumaihi, Faris, Moustafa, Mahmoud F., and Atia, Mohamed A. M.
- Published
- 2021
- Full Text
- View/download PDF
3. In Silico Mining of Terpenes from Red-Sea Invertebrates for SARS-CoV-2 Main Protease (Mpro) Inhibitors
- Author
-
Ibrahim, Mahmoud A. A., Abdelrahman, Alaa H. M., Mohamed, Tarik A., Atia, Mohamed A. M., Al-Hammady, Montaser A. M., Abdeljawaad, Khlood A. A., Elkady, Eman M., Moustafa, Mahmoud F., Alrumaihi, Faris, Allemailem, Khaled S., El-Seedi, Hesham R., Paré, Paul W., Efferth, Thomas, and Hegazy, Mohamed-Elamir F.
- Subjects
Binding Sites ,SARS-CoV-2 ,Terpenes ,COVID-19 ,marine natural products ,Hydrogen Bonding ,molecular docking ,Molecular Dynamics Simulation ,Invertebrates ,Lopinavir ,Article ,molecular dynamics ,COVID-19 Drug Treatment ,drug discovery ,lcsh:QD241-441 ,Molecular Docking Simulation ,Viral Matrix Proteins ,SARS-CoV-2 main protease ,lcsh:Organic chemistry ,Animals ,Humans ,Thermodynamics ,Protease Inhibitors ,virtual drug screening ,Protein Binding - Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative agent for the COVID-19 pandemic, which generated more than 1.82 million deaths in 2020 alone, in addition to 83.8 million infections. Currently, there is no antiviral medication to treat COVID-19. In the search for drug leads, marine-derived metabolites are reported here as prospective SARS-CoV-2 inhibitors. Two hundred and twenty-seven terpene natural products isolated from the biodiverse Red-Sea ecosystem were screened for inhibitor activity against the SARS-CoV-2 main protease (Mpro) using molecular docking and molecular dynamics (MD) simulations combined with molecular mechanics/generalized Born surface area binding energy calculations. On the basis of in silico analyses, six terpenes demonstrated high potency as Mpro inhibitors with ΔGbinding ≤ −40.0 kcal/mol. The stability and binding affinity of the most potent metabolite, erylosides B, were compared to the human immunodeficiency virus protease inhibitor, lopinavir. Erylosides B showed greater binding affinity towards SARS-CoV-2 Mpro than lopinavir over 100 ns with ΔGbinding values of −51.9 vs. −33.6 kcal/mol, respectively. Protein–protein interactions indicate that erylosides B biochemical signaling shares gene components that mediate severe acute respiratory syndrome diseases, including the cytokine- and immune-signaling components BCL2L1, IL2, and PRKC. Pathway enrichment analysis and Boolean network modeling were performed towards a deep dissection and mining of the erylosides B target–function interactions. The current study identifies erylosides B as a promising anti-COVID-19 drug lead that warrants further in vitro and in vivo testing.
- Published
- 2021
4. Exploring Natural Product Activity and Species Source Candidates for Hunting ABCB1 Transporter Inhibitors: An In Silico Drug Discovery Study.
- Author
-
Ibrahim, Mahmoud A. A., Abdeljawaad, Khlood A. A., Abdelrahman, Alaa H. M., Jaragh-Alhadad, Laila A., Oraby, Hesham Farouk, Elkaeed, Eslam B., Mekhemer, Gamal A. H., Gabr, Gamal A., Shawky, Ahmed M., Sidhom, Peter A., Soliman, Mahmoud E. S., Moustafa, Mahmoud F., Paré, Paul W., and Hegazy, Mohamed-Elamir F.
- Subjects
DRUG discovery ,P-glycoprotein ,NATURAL products ,MOLECULAR dynamics ,MOLECULAR docking - Abstract
The P-glycoprotein (P-gp/ABCB1) is responsible for a xenobiotic efflux pump that shackles intracellular drug accumulation. Additionally, it is included in the dud of considerable antiviral and anticancer chemotherapies because of the multidrug resistance (MDR) phenomenon. In the search for prospective anticancer drugs that inhibit the ABCB1 transporter, the Natural Product Activity and Species Source (NPASS) database, containing >35,000 molecules, was explored for identifying ABCB1 inhibitors. The performance of AutoDock4.2.6 software to anticipate ABCB1 docking score and pose was first assessed according to available experimental data. The docking scores of the NPASS molecules were predicted against the ABCB1 transporter. Molecular dynamics (MD) simulations were conducted for molecules with docking scores lower than taxol, a reference inhibitor, pursued by molecular mechanics-generalized Born surface area (MM-GBSA) binding energy estimations. On the basis of MM-GBSA calculations, five compounds revealed promising binding affinities as ABCB1 inhibitors with ΔG
binding < −105.0 kcal/mol. The binding affinity and stability of the identified inhibitors were compared to the chemotherapeutic agent. Structural and energetical analyses unveiled great steadiness of the investigated inhibitors within the ABCB1 active site throughout 100 ns MD simulations. Conclusively, these findings point out that NPC104372, NPC475164, NPC2313, NPC197736, and NPC477344 hold guarantees as potential ABCB1 drug candidates and warrant further in vitro/in vivo tests. [ABSTRACT FROM AUTHOR]- Published
- 2022
- Full Text
- View/download PDF
5. In Silico Targeting Human Multidrug Transporter ABCG2 in Breast Cancer: Database Screening, Molecular Docking, and Molecular Dynamics Study.
- Author
-
Ibrahim, Mahmoud A. A., Badr, Esraa A. A., Abdelrahman, Alaa H. M., Almansour, Nahlah Makki, Mekhemer, Gamal A. H., Shawky, Ahmed M., Moustafa, Mahmoud F., and Atia, Mohamed A. M.
- Subjects
MOLECULAR docking ,MOLECULAR dynamics ,BREAST cancer ,EARLY detection of cancer ,MULTIDRUG resistance ,DOCKS - Abstract
ABCG2 is a substantial member of the ABC transporter superfamily that plays a significant role in multidrug resistance in cancer. Until recently, the 3D structure of ABCG2 has not been resolved, which resulted in the limitation of developing potential ABCG2 inhibitors using structure‐based drug discovery. Herein, eMolecules, ChEMBL, and ChEBI databases, containing >25 million compounds, were virtually screened against the ABCG2 transporter in homodimer form. Performance of AutoDock4.2.6 software to predict inhibitor‐ABCG2 binding mode and affinity were validated on the basis of available experimental data. The explored databases were filtered based on docking scores. The most potent hits with binding affinities higher than that of experimental bound ligand (MZ29) were then selected and subjected to molecular mechanics minimization, followed by binding energy calculation using molecular mechanics‐generalized Born surface area (MM‐GBSA) approach. Furthermore, molecular dynamics simulations for 50 ns, followed by MM‐GBSA binding energy calculations, were performed for the promising compounds, unveiling eight potential inhibitors with binding affinities <−55.8 kcal/mol. Structural and energetic analyses demonstrated the stability of the eight identified inhibitors over the 50 ns MD simulation. This research sheds light on the potentiality of the identified ABCG2 inhibitors as a therapeutic approach to overcome multidrug resistance cancer therapy. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
6. Blue Biotechnology: Computational Screening of Sarcophyton Cembranoid Diterpenes for SARS-CoV-2 Main Protease Inhibition.
- Author
-
Ibrahim, Mahmoud A. A., Abdelrahman, Alaa H. M., Atia, Mohamed A. M., Mohamed, Tarik A., Moustafa, Mahmoud F., Hakami, Abdulrahim R., Khalifa, Shaden A. M., Alhumaydhi, Fahad A., Alrumaihi, Faris, Abidi, Syed Hani, Allemailem, Khaled S., Efferth, Thomas, Soliman, Mahmoud E., Paré, Paul W., El-Seedi, Hesham R., and Hegazy, Mohamed-Elamir F.
- Abstract
The coronavirus pandemic has affected more than 150 million people, while over 3.25 million people have died from the coronavirus disease 2019 (COVID-19). As there are no established therapies for COVID-19 treatment, drugs that inhibit viral replication are a promising target; specifically, the main protease (M
pro ) that process CoV-encoded polyproteins serves as an Achilles heel for assembly of replication-transcription machinery as well as down-stream viral replication. In the search for potential antiviral drugs that target Mpro , a series of cembranoid diterpenes from the biologically active soft-coral genus Sarcophyton have been examined as SARS-CoV-2 Mpro inhibitors. Over 360 metabolites from the genus were screened using molecular docking calculations. Promising diterpenes were further characterized by molecular dynamics (MD) simulations based on molecular mechanics-generalized Born surface area (MM-GBSA) binding energy calculations. According to in silico calculations, five cembranoid diterpenes manifested adequate binding affinities as Mpro inhibitors with ΔGbinding < −33.0 kcal/mol. Binding energy and structural analyses of the most potent Sarcophyton inhibitor, bislatumlide A (340), was compared to darunavir, an HIV protease inhibitor that has been recently subjected to clinical-trial as an anti-COVID-19 drug. In silico analysis indicates that 340 has a higher binding affinity against Mpro than darunavir with ΔGbinding values of −43.8 and −34.8 kcal/mol, respectively throughout 100 ns MD simulations. Drug-likeness calculations revealed robust bioavailability and protein-protein interactions were identified for 340; biochemical signaling genes included ACE, MAPK14 and ESR1 as identified based on a STRING database. Pathway enrichment analysis combined with reactome mining revealed that 340 has the capability to re-modulate the p38 MAPK pathway hijacked by SARS-CoV-2 and antagonize injurious effects. These findings justify further in vivo and in vitro testing of 340 as an antiviral agent against SARS-CoV-2. [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
7. In Silico Mining of Terpenes from Red-Sea Invertebrates for SARS-CoV-2 Main Protease (M pro) Inhibitors.
- Author
-
Ibrahim, Mahmoud A. A., Abdelrahman, Alaa H. M., Mohamed, Tarik A., Atia, Mohamed A. M., Al-Hammady, Montaser A. M., Abdeljawaad, Khlood A. A., Elkady, Eman M., Moustafa, Mahmoud F., Alrumaihi, Faris, Allemailem, Khaled S., El-Seedi, Hesham R., Paré, Paul W., Efferth, Thomas, Hegazy, Mohamed-Elamir F., and Silva, Pedro
- Subjects
TERPENES ,SARS-CoV-2 ,COVID-19 pandemic ,COVID-19 ,HIV - Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative agent for the COVID-19 pandemic, which generated more than 1.82 million deaths in 2020 alone, in addition to 83.8 million infections. Currently, there is no antiviral medication to treat COVID-19. In the search for drug leads, marine-derived metabolites are reported here as prospective SARS-CoV-2 inhibitors. Two hundred and twenty-seven terpene natural products isolated from the biodiverse Red-Sea ecosystem were screened for inhibitor activity against the SARS-CoV-2 main protease (M
pro ) using molecular docking and molecular dynamics (MD) simulations combined with molecular mechanics/generalized Born surface area binding energy calculations. On the basis of in silico analyses, six terpenes demonstrated high potency as Mpro inhibitors with ΔGbinding ≤ −40.0 kcal/mol. The stability and binding affinity of the most potent metabolite, erylosides B, were compared to the human immunodeficiency virus protease inhibitor, lopinavir. Erylosides B showed greater binding affinity towards SARS-CoV-2 Mpro than lopinavir over 100 ns with ΔGbinding values of −51.9 vs. −33.6 kcal/mol, respectively. Protein–protein interactions indicate that erylosides B biochemical signaling shares gene components that mediate severe acute respiratory syndrome diseases, including the cytokine- and immune-signaling components BCL2L1, IL2, and PRKC. Pathway enrichment analysis and Boolean network modeling were performed towards a deep dissection and mining of the erylosides B target–function interactions. The current study identifies erylosides B as a promising anti-COVID-19 drug lead that warrants further in vitro and in vivo testing. [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
8. Rutin and flavone analogs as prospective SARS-CoV-2 main protease inhibitors: In silico drug discovery study.
- Author
-
Ibrahim, Mahmoud A.A., Mohamed, Eslam A.R., Abdelrahman, Alaa H.M., Allemailem, Khaled S., Moustafa, Mahmoud F., Shawky, Ahmed M., Mahzari, Ali, Hakami, Abdulrahim Refdan, Abdeljawaad, Khlood A.A., and Atia, Mohamed A.M.
- Subjects
- *
COVID-19 , *SARS-CoV-2 , *LOPINAVIR-ritonavir , *PROTEASE inhibitors , *RUTIN , *BINDING energy - Abstract
Coronavirus disease 2019 (COVID-19) is a new pandemic characterized by quick spreading and illness of the respiratory system. To date, there is no specific therapy for Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2). Flavonoids, especially rutin, have attracted considerable interest as a prospective SARS-CoV-2 main protease (Mpro) inhibitor. In this study, a database containing 2017 flavone analogs was prepared and screened against SARS-CoV-2 Mpro using the molecular docking technique. According to the results, 371 flavone analogs exhibited good potency towards Mpro with docking scores less than −9.0 kcal/mol. Molecular dynamics (MD) simulations, followed by molecular mechanics-generalized Born surface area (MM/GBSA) binding energy calculations, were performed for the top potent analogs in complex with Mpro. Compared to rutin, PubChem-129-716-607 and PubChem-885-071-27 showed better binding affinities against SARS-CoV-2 Mpro over 150 ns MD course with Δ G binding values of −69.0 and −68.1 kcal/mol, respectively. Structural and energetic analyses demonstrated high stability of the identified analogs inside the SARS-CoV-2 Mpro active site over 150 ns MD simulations. The oral bioavailabilities of probable SARS-CoV-2 Mpro inhibitors were underpinned using drug-likeness parameters. A comparison of the binding affinities demonstrated that the MM/GBSA binding energies of the identified flavone analogs were approximately three and two times less than those of lopinavir and baicalein, respectively. In conclusion, PubChem-129-716-607 and PubChem-885-071-27 are promising anti-COVID-19 drug candidates that warrant further clinical investigations. [Display omitted] • A database containing 2017 flavone analogs was prepared and screened against SARS-CoV-2 Mpro using in silico techniques. • PubChem-129-716-607 and PubChem-885-071-27 demonstrated higher binding affinities against Mpro than rutin and baicalein. • PubChem-129-716-607 and PubChem-885-071-27 exhibited high stability inside the Mpro active site over 150 ns MD simulations. • PubChem-129-716-607 and PubChem-885-071-27 manifested promising drug-likeness properties. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.